These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15055164)

  • 1. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 2. High rate of virologic failure with once-daily ddI/3TC/TDF.
    IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
    [No Abstract]   [Full Text] [Related]  

  • 3. Tenofovir drug interactions: ddI and d4T.
    TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
    [No Abstract]   [Full Text] [Related]  

  • 4. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract]   [Full Text] [Related]  

  • 5. Tenofovir--long term results from first-line therapy.
    TreatmentUpdate; 2003; 15(2):4-6. PubMed ID: 12693361
    [No Abstract]   [Full Text] [Related]  

  • 6. The importance of sequencing in treatment options.
    Berger DS
    Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
    MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
    [No Abstract]   [Full Text] [Related]  

  • 8. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
    MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
    [No Abstract]   [Full Text] [Related]  

  • 9. New uses for tenofovir: more questions about d4T.
    Proj Inf Perspect; 2003 Jan; (35):15-6. PubMed ID: 12647676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded access.
    Proj Inf Perspect; 1999 Sep; (28):8. PubMed ID: 11367366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 13. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir: FDA hearing on important new antiretroviral.
    James JS
    AIDS Treat News; 2001 Oct; (372):2-4. PubMed ID: 11702411
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenofovir DF on the horizon. Investigational nucleotide reverse transcriptor inhibitor could be on pharmacy shelves soon.
    Eagan L
    Posit Living; 2001; 10(5):21. PubMed ID: 11693102
    [No Abstract]   [Full Text] [Related]  

  • 17. Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
    Alcaide ML; Kolber M; Jayaweera D
    Int J STD AIDS; 2002 Nov; 13(11):795-6. PubMed ID: 12437905
    [No Abstract]   [Full Text] [Related]  

  • 18. Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
    Schouten J
    STEP Perspect; 1999; 99(3):16. PubMed ID: 11366864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney damage reported in some tenofovir users.
    TreatmentUpdate; 2003; 15(2):6-7. PubMed ID: 12693362
    [No Abstract]   [Full Text] [Related]  

  • 20. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
    Negredo E; Garrabou G; Puig J; Lòpez S; Morén C; Bellido R; Ayen R; Cardellach F; Miró O; Clotet B
    Antivir Ther; 2008; 13(2):231-40. PubMed ID: 18505174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.